Hypersomnia Foundation

Hypersomnia Foundation has been a member of Linktree for 3 years and joined in October 2022. The social media accounts linked to from Hypersomnia Foundation are: Instagram, TikTok, YouTube, Email. Besides social media accounts, hypersomniafoundation has populated their site with IH Day 2026 - #WhereInTheworldIH Graphic Gallery, Hey Sleepyhead, Hypersomnia Foundation YouTube Channel, Caught In This Riptide, Focused Projects Grant for Junior Investigators - AASM Foundation, THE SPOON PROJECT, Hypersomnia Foundation | Official Merchandise | Bonfire, Hypersomnia Foundation YouTube Channel, About the ONSTRIDE-2 study, Young Adults with Hypersomnia Group Chat, December UNIGHT – Navigating the holidays, Why 80% of sleep disorders go undiagnosed | Lindsay Scola | TEDxSonomaCounty, 2024 End of Year Campaign Social Media Toolkit, 2024 End of Year Campaign, #BeyondSleepy One Day Conference in Phoenix, AZ | Oct 10th, JUNE UNIGHT – *June 29th* register now, July Support4Supporters - July 8th, Illuminate Brain Fog | Sleep Consortium, Narcolepsy With Cataplexy Clinical Research Study, U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1｜Takeda Pharmaceuticals, Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia | Avadel Pharmaceuticals PLC, Enrollment is now open for the ALBA Study, PRIME SURVEY, Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses | Jazz Pharmaceuticals plc, The impact of idiopathic hypersomnia on the social lives of young adults, Share your experiences with idiopathic hypersomnia to help others., Strategic Research Grant - AASM Foundation, Clinical Trial in Low Sodium Oxybate is open for people with Idiopathic Hypersomnia | Mayo Clinic, Building a Global IH Community: Michelle Chadwick on Advocacy, Awareness, and Australia’s Challenges, Dismissed for Decades: Margie’s 30-Year Journey to an Idiopathic Hypersomnia Diagnosis, Rethinking Success, Safety, and Independence: Conversations for Young Adults With IH with Caitlin, Fighting to Be Heard: Taylor Jackson’s Journey Through Dismissal and Diagnosis with IH, The Future of Treatment with Orexin Agonists With Deborah Hartman, PhD, Navigating College with Idiopathic Hypersomnia with Laura Z., Insights on Adapting Radical Acceptance and Self Compassion as a PWIH With Caitlin, Breaking Barriers with Patient-Owned Data Platforms With Karmen Trzupek, How CBT May Help Manage Your Symptoms With Dr. Shelby Harris, Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia | Alkermes plc, Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc | Alkermes plc, Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program – Centessa Pharmaceuticals, Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 | Alkermes plc, Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia | Harmony Biosciences, Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy | Avadel Pharmaceuticals, Low-sodium oxybate improved symptoms in adults with idiopathic hypersomnia: A Plain Language Summary of Publication, Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 | Alkermes plc, HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY | Harmony Biosciences, Harmony Biosciences announces exclusive agreement to develop and commercialize TPM-1116, Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680, Press Release : Rare Sleep Disorder More Prevalent Than Previously Thought, Harmony Biosciences Press Release - FDA Grants Priority Review, Your Donation Makes a Difference - Hypersomnia Foundation, Visit Our Website, Top Resources from the Hypersomnia Foundation, Update or join the CoRDS Patient Registry!, CoRDS Fillable Form, Tips for Supporters - Hypersomnia Foundation, Subscribe to SomnusNooze, Videos & Podcasts - Hypersomnia Foundation, Things to consider when making an emergency medical plan, Anesthesia, Hospitalization and Emergency Planning tool kit, Sleep Hygiene and What It Means for People Who Have Hypersomnias - Hypersomnia Foundation, Health and Prescription Medication Insurance Denials and Appeals, Long-COVID & Sleep Disorders Study Report, I Have IH Campaign Reveals Patient and Supporter Perspectives on the Impact of Idiopathic Hypersomnia | Jazz Pharmaceuticals.